Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Zalifrelimab and Balstilimab with Cisplatin-Gemcitabine in MIBC
NCT04430036Phase 2Terminated
- Sponsor
- UT Health San Antonio
- Start
- Oct 2020
- Primary completion
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of zalifrelimab, balstilimab in muscle-invasive bladder cancer (MIBC), sponsored by UT Health San Antonio. Started Oct 2020; status: terminated.
02
Drugs
zalifrelimabbalstilimab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT04430036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04430036.